{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:49Z","timestamp":1789469149659,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Supported by Beijing Natural Science Foundation","award":["7254351"],"award-info":[{"award-number":["7254351"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07097-8","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:54:36Z","timestamp":1781207676000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy analysis of CAR-T cells against CD123-positive malignant tumors and exploration of the feasibility of combination therapy with venetoclax"],"prefix":"10.1007","volume":"105","author":[{"given":"Meng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yedi","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanxia","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"issue":"5","key":"7097_CR1","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M et al (2018) Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia [J]. N Engl J Med 378(5):449\u2013459","journal-title":"N Engl J Med"},{"issue":"2","key":"7097_CR2","first-page":"e1222","volume":"3","author":"S Pratap","year":"2020","unstructured":"Pratap S, Zhao ZJ (2020) Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia [J]. Cancer Rep (Hoboken) 3(2):e1222","journal-title":"Cancer Rep (Hoboken)"},{"issue":"22","key":"7097_CR3","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.1158\/1078-0432.CCR-17-3016","volume":"24","author":"O Beyar-Katz","year":"2018","unstructured":"Beyar-Katz O, Gill S (2018) Novel Approaches to Acute Myeloid Leukemia Immunotherapy [J]. Clin Cancer Res 24(22):5502\u20135515","journal-title":"Clin Cancer Res"},{"key":"7097_CR4","first-page":"1359","volume":"130","author":"KD Cummins","year":"2017","unstructured":"Cummins KD, Frey N, Nelson AM et al (2017) Treating Relapsed \/ Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells [J]. Blood 130:1359","journal-title":"Blood"},{"issue":"12","key":"7097_CR5","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL et al (2015) Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy [J]. Cancer Discov 5(12):1282\u20131295","journal-title":"Cancer Discov"},{"issue":"19","key":"7097_CR6","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","volume":"135","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Hirayama AV, Purushe J et al (2020) Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure [J]. Blood 135(19):1650\u20131660","journal-title":"Blood"},{"key":"7097_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3389\/fonc.2019.00767","volume":"9","author":"Y Cao","year":"2019","unstructured":"Cao Y, Lu W, Sun R et al (2019) Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed\/Refractory B-Cell Non-hodgkin Lymphoma [J]. Front Oncol 9:767","journal-title":"Front Oncol"},{"key":"7097_CR8","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.3389\/fimmu.2020.01787","volume":"11","author":"L You","year":"2020","unstructured":"You L, Han Q, Zhu L et al (2020) Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells [J]. Front Immunol 11:1787","journal-title":"Front Immunol"},{"issue":"3","key":"7097_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood.2020009081","volume":"138","author":"JB Lee","year":"2021","unstructured":"Lee JB, Khan DH, Hurren R et al (2021) Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production [J]. Blood 138(3):234\u2013245","journal-title":"Blood"},{"issue":"10","key":"7097_CR10","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1158\/2159-8290.CD-21-1026","volume":"12","author":"YG Lee","year":"2022","unstructured":"Lee YG, Guruprasad P, Ghilardi G et al (2022) Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer [J]. Cancer Discov 12(10):2372\u20132391","journal-title":"Cancer Discov"},{"key":"7097_CR11","doi-asserted-by":"publisher","first-page":"608167","DOI":"10.3389\/fimmu.2020.608167","volume":"11","author":"M Yang","year":"2020","unstructured":"Yang M, Wang L, Ni M et al (2020) Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells [J]. Front Immunol 11:608167","journal-title":"Front Immunol"},{"issue":"5","key":"7097_CR12","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","volume":"18","author":"G Liu","year":"2021","unstructured":"Liu G, Rui W, Zhao X et al (2021) Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment [J]. Cell Mol Immunol 18(5):1085\u20131095","journal-title":"Cell Mol Immunol"},{"key":"7097_CR13","doi-asserted-by":"crossref","unstructured":"Hirobe S, Imaeda K, Tachibana M et al (2022) The effects of Chimeric Antigen Receptor (CAR) hinge domain post-translational modifications on CAR-T cell activity. Int J Mol Sci 23(7)","DOI":"10.3390\/ijms23074056"},{"issue":"8","key":"7097_CR14","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY, Patel S, Muffly L et al (2021) CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial [J]. Nat Med 27(8):1419\u20131431","journal-title":"Nat Med"},{"issue":"8","key":"7097_CR15","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.ymthe.2017.04.017","volume":"25","author":"S Arcangeli","year":"2017","unstructured":"Arcangeli S, Rotiroti MC, Bardelli M et al (2017) Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia [J]. Mol Ther 25(8):1933\u20131945","journal-title":"Mol Ther"},{"key":"7097_CR16","doi-asserted-by":"crossref","unstructured":"Pan R, Ryan J, Pan D et al (2022) Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell 185(9)","DOI":"10.1016\/j.cell.2022.03.030"},{"key":"7097_CR17","doi-asserted-by":"crossref","unstructured":"Ye L, Park JJ, Peng L et al (2022) A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metab 34(4)","DOI":"10.1016\/j.cmet.2022.02.009"},{"issue":"6","key":"7097_CR18","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1158\/2159-8290.CD-RW2022-054","volume":"12","author":"PRODH2-Mediated Proline","year":"2022","unstructured":"PRODH2-Mediated Proline (2022) Metabolism Boosts CAR T-cell Effector Function [J]. Cancer Discov 12(6):1405","journal-title":"Cancer Discov"},{"key":"7097_CR19","doi-asserted-by":"crossref","unstructured":"Qu Y, Dunn ZS, Chen X et al (2022) Adenosine deaminase 1 overexpression enhances the antitumor efficacy of chimeric antigen receptor-engineered T cells. Hum Gene Ther 33(5\u20136): 223\u2009\u2013\u200936","DOI":"10.1089\/hum.2021.050"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07097-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07097-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07097-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:43:07Z","timestamp":1789465387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07097-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7097"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07097-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of Tianjin First Central Hospital. The need for informed consent was waived due to the retrospective nature of the study and because the data were anonymously analyzed. Written informed consent was obtained from the individual for the publication of any potentially identifiable images or data included in this article.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"378"}}